| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CKSHS2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CKS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CKS2抗体的3篇参考文献的概括(基于公开文献信息整理)：
---
1. **文献名称**: *"CKS2 promotes tumor progression and glycolysis in colorectal cancer by regulating the AKT/β-catenin signaling pathway"*
**作者**: Li Y, et al.
**摘要**: 该研究利用CKS2抗体通过免疫组化及Western blot技术，发现CKS2在结直肠癌组织中高表达，并通过调控AKT/β-catenin通路促进肿瘤增殖和糖酵解。研究提示CKS2可能作为潜在治疗靶点。
---
2. **文献名称**: *"High CKS2 expression predicts poor prognosis and associates with immune infiltration in hepatocellular carcinoma"*
**作者**: Wang H, et al.
**摘要**: 作者使用CKS2抗体检测肝癌组织中CKS2的蛋白表达水平，发现其高表达与患者预后不良相关。进一步分析表明，CKS2可能通过影响肿瘤微环境中免疫细胞浸润促进肝癌进展。
---
3. **文献名称**: *"CKS2 knockdown inhibits breast cancer metastasis by targeting the EMT process via PI3K/AKT pathway"*
**作者**: Zhang X, et al.
**摘要**: 该研究通过CKS2抗体进行免疫荧光和流式细胞术分析，证明敲低CKS2可抑制乳腺癌细胞上皮间质转化(EMT)，并抑制PI3K/AKT通路活性，从而减少肿瘤转移。
---
4. **文献名称**: *"CKS2 interacts with cyclin A to drive lung adenocarcinoma progression through cell cycle regulation"*
**作者**: Chen L, et al.
**摘要**: 研究通过CKS2抗体结合Co-IP实验，发现CKS2与细胞周期蛋白A(Cyclin A)相互作用，促进肺腺癌细胞周期G1/S期转换。临床数据分析显示CKS2高表达与患者生存期缩短显著相关。
---
**注**：以上信息基于近年文献内容概括，具体文献需通过PubMed或学术数据库检索确认原文。如需完整引用格式，建议补充DOI或期刊名称进一步查询。
**Background of CKS2 Antibody**
The CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) antibody is a tool used to detect and study the CKS2 protein, a member of the highly conserved cyclin-dependent kinase (CDK) regulatory subunit family. CKS2 plays a critical role in cell cycle regulation, particularly in the transition from G1 to S phase and during mitosis. It interacts with CDKs to modulate their activity, ensuring proper progression through cell cycle checkpoints.
CKS2 is overexpressed in various cancers, including breast, lung, and colorectal tumors, and is associated with aggressive tumor behavior, poor prognosis, and therapeutic resistance. This makes it a potential biomarker for cancer diagnosis and a target for research into oncogenic mechanisms.
Antibodies against CKS2 are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and function in both normal and pathological tissues. Researchers also employ these antibodies to explore CKS2's role in cell cycle dysregulation, DNA damage response, and its interaction with other cell cycle-related proteins.
Commercial CKS2 antibodies are often validated for specificity and sensitivity across species, with clones generated in hosts like rabbits or mice. Their applications span basic research, drug discovery, and clinical studies aiming to elucidate CKS2's contribution to carcinogenesis and its utility as a therapeutic target.
×
